Accession Therapeutics presents first-in-human ATTEST trial at the European Society for Medical Oncology (ESMO) Congress 2025

At the ESMO Congress 2025, taking place between 17-21 October, Accession Therapeutics are sharing details of our ATTEST study, a first-in-human Phase 1 trial of ATTR-01 (TROCEPT-01) in patients with selected epithelial tumours.

ATTR-01 is a next-generation oncolytic adenovirus developed using Accession's proprietary TROCEPT platform. It is designed to target the cancer marker αvβ6 integrin and express an anti-PD-L1 antibody payload locally within the tumour micro-environment following intravenous delivery.

The Accession Therapeutics Team at ESMO 2025

The ATTEST study (NCT06977737)  is now open and will involve patients with non-small cell lung cancer, bladder, pancreatic, head and neck, cholangiocarcinoma and endometrial cancers across multiple leading sites in the UK and Spain. 

Hardev Pandha, Medical Director at Accession Therapeutics, said:

“ATTR-01 represents a new way to deliver checkpoint inhibition where it’s needed most - within tumours - while minimising systemic exposure.”

📍 Find us at Poster #3780

Click to view poster pdf

Poster Title: A Phase 1 Study of ATTR-01, a Novel Oncolytic Adenovirus Targeting αvβ6 Integrin, Expressing an Anti-PD-L1 Antibody Payload in Tumour Following Intravenous Delivery in Patients with Selected Epithelial Tumours